Browsing Tag
Hong Kong biotech
4 posts
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after positive Phase III trial
Akeso files gumokimab for NMPA review in ankylosing spondylitis. Find out how this move expands its autoimmune pipeline beyond oncology.
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.
Keymed Biosciences’ CM336 shows sustained remission in AIHA patients after CAR-T failure
Keymed Biosciences’ CM336 delivers 6-month remission in AIHA post-CAR-T failure, with NEJM publication and bullish stock sentiment. Find out what’s next for the biotech.